Merck’s New COVID Drug Is Making News — How Does It Compare to Ivermectin?
In his latest video, John Campbell, Ph.D., compared ivermectin, whose use as a COVID treatment has been widely criticized by mainstream media, with Merck’s new COVID drug, Molnupiravir, which is garnering positive media coverage.
In his latest video, John Campbell, Ph.D., compared ivermectin, whose use as a COVID treatment has been widely criticized by mainstream media, with Merck’s new COVID drug, Molnupiravir, which has been the subject of glowing media attention.
Campbell, a UK-based nurse teacher, cited several studies as he compared the two treatments on the basis of effectiveness, safety and cost. He first turned to a paper in the Austin Journal of Pharmacology and Therapeutics, “Drugs Shown to Inhibit SARS-Cov-2 in COVID-19 Disease: Comparative Basic and Clinical Pharmacology of Molnupiravir and Ivermectin.”
The peer-reviewed paper refers to ivermectin as the most studied “repurposed” medication globally, and notes that it is approved by the U.S. Food and Drug Administration and “classified by the World Health Organization (WHO) as an ‘essential’ broad spectrum antiparasitic, antibiotic, and has demonstrated broad antiviral activity against RNA viruses, including HIV, Zika, MERS and coronavirus.”
“And of course, ivermectin also won the Nobel Prize in 2015,” Campbell said.
According to the paper, Campbell said, Molnupiravir — though still going through trials and safety testing — is believed to “work against seasonal and pandemic flu, MERS, coronavirus and SARS-CoV-2.” The paper’s author noted that Molnupiravir does not inhibit inflammation, whereas ivermectin does.
How do the two drugs compare on cost? Ivermectin is exponentially cheaper than Merck’s new Molnupiraravir.
The cost of a complete five-day course of Molnupiravir is $700 — or $70 per pill. That amounts to a 4,000% markup over what it costs Merck to make the drug.
On effectiveness, Molnupiravir is lacking data. The only publicly available clinical data on Molnupiravir comes from a Merck press statement claiming the new drug is 50% effective against hospitalizations and deaths, when used as an early treatment.
For ivermectin, using publicly available data, Campbell referred to one peer-reviewed study that pegs ivermectin’s effectiveness in early treatment at 62%, and an ongoing meta-analysis which shows ivermectin is 66% effective in early treatment and 86% effective as a prophylactic.
Using VigiBase, a WHO database on pharmaceutical safety data, Campbell showed that out of 3.7 billion doses given of ivermectin there have been only 5,693 reports of adverse events — far fewer, according to Campbell, than the number of adverse event reports associated with amoxicillin and ibuprofen, both widely used and considered safe.
Comparable safety information for Merck’s Molnupiravir is not yet available, as trials and studies are still ongoing. But Campbell did raise concern about Molnupiravir’s mutagenic properties. He cited the Austin Journal of Pharmacology and Therapeutics paper which states, “there is some concern about the safety of [Molnupiravir’s] NHC-nucleoside triphosphate, which is mutagenic to mammalian cells.”
According to Campbell, Merck denies this is a problem. But the paper suggests, at the very least,” it needs looking into,” Campbell said.
Watch the video here:
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of Children’s Health Defense.
“Merck denies this is a problem.”
Ha, ha, ha….seriously, at some point you have to just look at this as theater of the absurd.
Due to Merck’s denial, our corrupt government and complicit mainstream media and medicine also will not see a problem.
It’s called blindness.
Two Indian Drugmakers have ended their trials of molnupiravir. They should have just followed the success of their countrymen in Uttar Pradesh as ivermectin brought COVID deaths down to ZERO.
The interesting part: Merck earlier suspended its own development of it due to…..wait for it…..because many patients reached a phase of the disease that is too late for an antiviral drug to provide much help.
The Spartacus Paper and states:
Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford’s ludicrous RECOVERY study, the intervention is too late to have any positive effect.
This fact, while taken into account for their “golden child,” drug is completely ignored by those denying the efficacy of ivermectin.
There have been 63 AND COUNTING studies involving 26,000 patients showing a 96% reduction in DEATH using ivermectin.
That’s a big deal. BIG!
A source with the Drug Controller General of India said molnupiravir has not shown “significant efficacy” against moderate COVID. Aurobindo and MSN are conducting studies on patients with mild COVID.